Each year, over 180,000 people worldwide are diagnosed with multiple myeloma, a type of blood cancer where abnormal plasma cells grow in the bone marrow. This cancer is the second most common blood cancer globally, and the survival rate after five years is currently just under 60 percent. For patients whose disease returns after treatment or does not respond to standard medicines, the situation becomes very difficult.
However, a new treatment approach is showing great promise. On July 23, 2026, Johnson & Johnson released positive early results from a clinical study called MonumenTAL-6. This study looked at patients with multiple myeloma that had returned or resisted treatment, and who had already tried one to four previous treatments.
The trial tested a combination of two drugs, TECVAYLI and TALVEY. The results were impressive: this combination lowered the chance of the disease getting worse or the patient dying by 89 percent compared to standard care. The combination also reduced the overall risk of death by 62 percent.
Researchers stated that these results are the best ever seen in a late-stage trial for this type of immunotherapy in patients with relapsed or refractory multiple myeloma. The study was so promising that an independent committee decided to reveal the results early.
These drugs work as bispecific antibodies, acting like bridges. They connect a patient's immune T-cells to the cancer cells, bringing the immune system directly to the tumor. TECVAYLI targets a protein called BCMA, and TALVEY targets GPRC5D. MonumenTAL-6 is the first late-stage trial to test attacking both these targets at the same time.
Ajay K. Nooka from Emory University School of Medicine mentioned that the drugs produced strong and lasting effects. He believes this approach of targeting both BCMA and GPRC5D offers a valuable new option for doctors. The study also compared the drug combination to TALVEY with pomalidomide, which reduced the risk of progression or death by 73 percent compared to standard therapies. Side effects were consistent with the known safety profiles of the individual drugs.